April 30, 2014: Speaker: Charles A. Crecelius, MD, PhD, CMD
1. Discuss recent regulatory changes regarding antipsychotic prescribing.
2. Review recent national efforts to decrease antipsychotic use.
3. Compare the role of various team members in ensuring appropriate antipsychotic use.
4. Recognize the elements of an effective gradual dose reduction program.
To learn more about this webinar, please visit Primaris at http://primaris.org/calendar/reducing-antipsychotic-use-in-nursing-homes-a-team-approach, or view the flyer here: Reducing Antipsychotic Use April 30, 2014.
Cat Without a Tail
Do you see a TIGER in your percentages when you expect a KITTEN? Are unexpected names on your Quality Measure (QM) Report for antipsychotic drug usage? Even the “appropriate” diagnosis of Schizophrenia will trigger the measure if not correctly reported. Schizophrenia, Tourette’s, and Huntington’s are the three accepted diagnoses for the use of an antipsychotic. Report these on the pre-printed section of the Minimum Data Set (MDS) Resident Assessment by checking I6000 for Schizophrenia, I5350 for Tourette’s Syndrome, and/or I5250 for Huntington’s Disease. In I8000 Additional active diagnoses, you may manually input “Schizophrenia with a tail.” One example is “Schizophrenia with Psychosis.” Please view CAT Tip #7 here: CAT_Tip_7. View more tips at http://primaris.org/tool. The Missouri Local Area Network for Excellence (MOLANE) is the state coalition for Advancing Excellence.
Hearing the Voice of Persons Living with Dementia
April 18, 2014: Conversations with Carmen… A Monthly Webinar
Guest: Megan Hannan, MS, Action Pact Consultant, Developer of PersonFirst®, author of Becoming Who They Were. To learn more and register for this web-based talk show, please visit www.actionpact.com/calendar/event_details/conversations_with_carmen_webinar.
March 21, 2014: Conversations with Carmen
Guest: Dan Cohen, MSW, Founder and Executive Director of Music & Memory
Rooted in neuroscience research, the results are described as “nothing short of miraculous” and certainly contribute to efforts to reduce anti-psychotics. To learn more and register for this web-based talk show, please visit www.actionpact.com/calendar/event_details/conversations_with_carmen_webinar or click here to register.
“Help, help, help, help, help.” The repetition of a word or question is likely a cry for comfort and security. Learn ways to make a connection with those who have dementia. View Tip #6 here: CAT Tip #6, or visit http://primaris.org/tool/changing-antipsychotic-thinking-cat-calls.
View more tips at http://primaris.org/tool. The Missouri Local Area Network for Excellence (MOLANE) is the state coalition for Advancing Excellence.
CMS is tracking the progress of the Partnership to Improve Dementia Care in Nursing Homes by reviewing publicly reported MDS quality measures. The official measure of the Partnership is the percentage of long-stay nursing home residents who are receiving an antipsychotic medication, excluding those residents diagnosed with schizophrenia, Huntington’s Disease or Tourette’s Syndrome.
Since the Partnership began in 2012, this data indicates Missouri’s percentage rates have dropped every quarter, with an overall decrease of 9.17 percent. This is encouraging and shows that Missouri is making improvements towards decreasing the use of antipsychotic medications for residents with dementia when their use is not indicated or appropriate. Please view the trend update here: CMS Trend Update – Antipsychotic Drug Use in Nursing Homes.
February 26, 2014: Presentation topics include the critical role of both state and federal surveyors in the implementation of the partnership, the importance of leadership, and the correlation between proper pain assessment and antipsychotic medication use. A question and answer session will follow.
These calls are free of charge. Registration is required. For detailed information, please visit CMS at www.cms.gov/Outreach-and-Education/Outreach/NPC/National-Provider-Calls-and-Events.html, or register at www.eventsvc.com/blhtechnologies/register/f32af1b2-3be3-4015-bd0f-3a7f529a867b.